

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

**(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING
HELD ON JUNE 18, 2026; AND
(2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND
ABOLISHMENT OF THE SUPERVISORY COMMITTEE**

References are made to (i) the circular (the “**Circular**”) and (ii) the notice (the “**Notice**”) both dated May 27, 2026 issued by Medtide Inc. (the “**Company**”) in relation to the 2025 annual general meeting of the Company (the “**AGM**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

THE 2025 ANNUAL GENERAL MEETING

The Board is pleased to announce that the AGM was held at 9:00 a.m. on Thursday, June 18, 2026 at No. 69, 12 Street, Qiantang District, Hangzhou, Zhejiang, the PRC.

As at the time of the AGM, the Company had a total of 141,800,000 H Shares in issue. None of the H Shares was held as treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited), and no voting rights attached to the treasury Shares may be exercised at the AGM. The total number of Shares entitling the holders to attend and vote for or against all the resolutions in the Notice proposed at the AGM was 141,800,000. There were no repurchased Shares which are pending cancellation and accordingly should be excluded from the total number of issued Shares for the purposes of the AGM. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed for consideration and approval by the Shareholders at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholders were required to abstain from voting at the AGM under the Listing Rules and none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed for consideration and approval by the Shareholders at the AGM.

The AGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Listing Rules and the articles of association of the Company. All Directors, namely, Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, Ms. Li Lingmei, Mr. Wu Yihui, Dr. Yu Cheung Hoi, Dr. Zhu Xun and Mr. Xia Xinsheng, attended the AGM in person or by electronic means.

The Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

All the resolutions as set out in the Notice were put to vote by way of poll by the Shareholders (including their proxies and authorized representatives) at the AGM.

POLL RESULTS OF THE AGM

The poll results of the proposed resolutions (the “**Resolutions**”) at the AGM were as follows:

ORDINARY RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the 2025 report of the Board.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
2.	To consider and approve the 2025 Work Report of the Supervisory Committee.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
3.	To consider and approve the 2025 Audited Consolidated Financial Statements.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
4.	To consider and approve the 2025 Annual Report.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
5.	To consider and approve the re-election of Directors.			
	(i) To re-elect Dr. Xu Qi as an executive Director.	114,542,375 (99.329837%)	772,800 (0.670163%)	0 (0.000000%)
	(ii) To re-elect Dr. Li Xiang as an executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(iii) To re-elect Ms. Li Xiangli as an executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(iv) To re-elect Ms. Cheng Tao as an executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(v) To re-elect Ms. Li Lingmei as an executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(vi) To re-elect Mr. Wu Yihui as a non-executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(vii) To re-elect Dr. Yu Cheung Hoi as an independent non-executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(viii) To re-elect Dr. Zhu Xun as an independent non-executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	(ix) To re-elect Mr. Xia Xinsheng as an independent non-executive Director.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)

ORDINARY RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
6.	To consider and approve the 2025 and 2026 Directors' remuneration package.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
7.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for 2026, and to approve to authorize the Board to determine their remunerations and enter into the relevant agreements.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
SPECIAL RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
8.	To consider and approve the proposed granting of the general mandate to the Board to repurchase H Shares.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)
9.	To consider and approve the proposed granting of the general mandate to the Board to issue Shares and sale or transfer of treasury shares.	115,281,175 (99.970516%)	34,000 (0.029484%)	0 (0.000000%)
10.	To consider and approve the Proposed Amendments to the Articles of Association and abolishment of the Supervisory Committee.	115,315,175 (100.000000%)	0 (0.000000%)	0 (0.000000%)

Note:

- (1) Please refer to the Circular for the full text of the Resolutions. Ordinary resolutions shall be passed by votes representing more than one-half of the voting rights held by the Shareholders (including proxies thereof) attending the AGM. Special resolutions shall be passed by votes representing at least two-thirds of the voting rights held by the Shareholders (including proxies thereof) attending the AGM.

As more than one-half of the votes were cast in favour of ordinary resolutions no. 1 to 7, and at least two-thirds of the votes were cast in favour of special resolutions no. 8 to 10, all resolutions proposed at the AGM were duly passed by way of poll by the Shareholders.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE

A special resolution was passed by the Shareholders at the AGM to approve the amendments to the Articles of Association and abolishment of the Supervisory Committee. Accordingly, upon the conclusion of the AGM, the amended Articles of Association shall become effective and the Company will no longer have the Supervisory Committee, and the current members of the Supervisory Committee shall cease to hold office as Supervisors from the date of the AGM. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.medtideinc.com).

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Dr. Xu Qi

Chairwoman and Chief Executive Officer

Hong Kong, June 18, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).